Physician profile
Mark S Armitage
NPI 1912952847
$10,901.55
in general payments reported to CMS, 2019-2025
56 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,859 · 2020: $761 · 2021: $1,631 · 2022: $1,220 · 2023: $1,800 · 2024: $1,844 · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,429.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,566.29 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,504.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $962.35 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $797.52 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $751.28 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $533.64 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $393.26 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.77 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $241.70 | 2019-2022 | |
| Amgen INC. | $209.59 | 2019-2025 | Repatha, Otezla, Repatha |
| Corium, LLC | $180.11 | 2023 | Adlarity |
| Exact Sciences Corporation | $165.84 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $165.23 | 2020-2025 | |
| Boston Scientific Corporation | $163.51 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.05 | 2023-2025 | Xifaxan, Trulance |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Armitage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.